Table 2.
Description of follow-up data and outcome events observed in the Scottish and STOP-HCV cohorts.
| Cohort | No. of individuals | Person years (PYs) |
Outcome |
|||||
|---|---|---|---|---|---|---|---|---|
| Total | Mean per patient | Median per patient | Event | No. of events | Crude rate, per 1,000 PYs (95% CI) | 3-year cumulative incidence (%) | ||
| Scottish cohort | 2,139 | 8,380 | 3.9 | 3.5 | HCC | 118 | 14.1 (11.8–16.9) | 3.3% (2.6–4.2) |
| Non-HCC mortality | 214 | 25.5 (22.3–29.2) | 8.5% (7.2–9.8) | |||||
| Drug-related mortality | 52 | 6.2 (4.7–8.1) | 2.2% (1.6–2.9) | |||||
| External causes mortality | 12 | 1.4 (0.8–2.5) | 0.6% (0.3–1.0) | |||||
| Non-HCC liver mortality | 45 | 5.4 (4.1–7.2) | 2.1% (1.5–2.8) | |||||
| All-cause mortality | 278 | 32.2 (28.6–36.2) | 9.8% (8.5–11.2) | |||||
| STOP-HCV cohort | 606 | 2,041 | 3.4 | 3.7 | HCC | 40 | 19.60 (14.4–26.7) | 5.1% (3.5–7.0) |
| Non-HCC mortality | 36 | 17.6 (12.7–24.5) | 5.0% (3.5–7.0) | |||||
| Drug-related mortality | 3 | 1.5 (0.5–4.6) | 0.5% (0.1–1.4) | |||||
| External causes mortality | 0 | 0 | 0 | |||||
| Non-HCC liver mortality | 18 | 8.8 (5.6–14.0) | 2.2% (1.2–3.6) | |||||
| All-cause mortality | 50 | 23.9 (18.1–31.6) | 7.3% (5.4–9.6) | |||||
Drug-related, external causes, and non-HCC liver mortality represent specific types of non-HCC mortality.
HCC, hepatocellular carcinoma; STOP-HCV, STratified medicine to Optimise Treatment of Hepatitis C Virus.